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The pericardial ﬂuid (PF) is contained in the pericardial sac
surrounding the heart. MicroRNA (miRNA) exchange via exo-
somes (endogenous nanoparticles) contributes to cell-to-cell
communication. We investigated the hypotheses that the PF
is enriched with miRNAs secreted by the heart and that it
mediates vascular responses through exosome exchange of
miRNAs. The study was developed using leftover material
from aortic valve surgery. We found that in comparison with
peripheral plasma, the PF contains exosomes enriched with
miRNAs co-expressed in patients’ myocardium and vascula-
ture. At a functional level, PF exosomes improved survival, pro-
liferation, and networking of cultured endothelial cells (ECs)
and restored the angiogenic capacity of ECs depleted (via Dicer
silencing) of their endogenous miRNA content. Moreover, PF
exosomes improved post-ischemic blood ﬂow recovery and
angiogenesis in mice. Mechanistically, (1) let-7b-5p is proan-
giogenic and inhibits its target gene, TGFBR1, in ECs; (2) PF
exosomes transfer a functional let-7b-5p to ECs, thus reducing
their TGFBR1 expression; and (3) let-7b-5p depletion in PF
exosomes impairs the angiogenic response to these nanopar-
ticles. Collectively, our data support the concept that PF exo-
somes orchestrate vascular repair via miRNA transfer.
INTRODUCTION
The pericardial ﬂuid (PF) is an ultraﬁltrate of plasma contained
within the double-walled pericardial sac (also known as pericardium)
that surrounds the heart and the roots of the great vessels (ascending
aorta, superior and inferior vena cavae, pulmonary arteries and
pulmonary veins) bringing blood to and from the heart cells (see
Figure S1).1 The pericardium is composed of two layers: (1) the super-
ﬁcial ﬁbrous pericardium, composed of connective tissue, is contin-
uous with the tunica adventitia of the great blood vessels and anchors
the heart to the surrounding walls, and (2) the serous pericardium,
composed of mesothelial cells. The serous pericardium is in turn
formed by a parietal layer that fuses with the ﬁbrous pericardium at
the great vessels roots and the epicardium, which sits on and signals
to the myocardium.2 Proteins introduced at the cavity surface of
the endocardium can cross this layer, move between the myocardial
cells, and accumulate under the epicardial mesothelium.3 Moreover,
myocardial interstitial ﬂuid can be drained from the subendocardium
to the subepicardium via a network of intramyocardial lymphatic
capillaries.4 Subsequently, molecules can be transported from the
pericardial cavity to the peripheral circulation by the thoracic duct
via the parietal pericardium, by the right lymphatic duct via the right
pleural cavity,5 or through the capillary network and the venous sys-
tem.6,7 Cardiac enzymes and troponins are present at higher levels in
the PF than the peripheral blood, and increased levels of these mole-
cules are used to aid the diagnosis of fatal myocardial infarct post-
mortem.8,9 Additionally, the PF contains biologically active factors
and components, of possible myocardial origin, including atrial and
brain natriuretic peptides and endothelin-1.10 From the above, the
myocardial contribution to PF content is apparent, and we reasoned
that the PF composition might reﬂect, at least in part, the myocar-
dium expression proﬁle in health and disease.
MicroRNAs (miRNAs) are post-transcriptional inhibitors of gene
expression, which act by provoking either the degradation or func-
tional inhibition of their mRNA targets.11 The interaction between
a miRNA and its targeted mRNAs happens within the RNA-induced
silencing complex (RISC), which includes the Argonaute-2 (AGO-2)
protein and the enzyme Dicer. Dicer also executes the ﬁnal matura-
tion step in miRNA biogenesis.11 miRNAs contribute to cardiovascu-
lar development, homeostasis, and disease.11 miRNAs can be released
in biologically active forms by the parental cells, and they are stable in
biological ﬂuids, thus representing novel biomarker candidates.12 In
fact, resilience of extracellular miRNAs is granted through different
partnerships, such as with extracellular vesicles (EVs), lipoprotein
complexes, and RNA-binding proteins or protein complexes,
including AGO-2.11 Exosomes are the smallest (30–120 nm in
size) of the known endogenous EVs. Exosomes have an endosomal
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origin and are retained within the multivesicular bodies (MVBs) as a
result of endosome compartmentalization, being released when the
latter fuse with the cell membrane.13 Exosomal miRNAs can be
taken-up by non-parental cells, thus inﬂuencing their gene expression
and ultimately working as cell-to-cell messengers in local and distant
micro-communication mechanisms.11 The presence of miRNAs in
the PF has been recently described.10 However, whether the PF
miRNAs are of cardiac origin, if they are released via EVs, and their
functional relevance have remained unaddressed.
Exosomes’ molecular cargo is variable and dependent on the
parental cell type and the environment. It is therefore intuitive
that the actions of exosomes are disparate. Within the cardiovascular
area, exosomes were reported to exert direct actions on cultured car-
diac myocytes, including promoting hypertrophy14 and survival.15
Some pioneering human studies on circulating exosomes have
focused at ﬁnding new clinical biomarkers, particularly in the
oncology area, in which the concept of exosomes as “liquid biopsies”
enriched with cancer cell-derived factors is receiving attention.16
However, the characterization of the exosomes present in human
biological ﬂuids and their possible role as cell-to-cell communicators
of cardiovascular relevance is still undeveloped. We have recently
provided preliminary evidence that exosomes containing high levels
of cardiovascular miRNAs are trafﬁcked out of the heart to reach the
peripheral blood in patients undergoing cardiac surgery using car-
diopulmonary bypass.17 This is an acute scenario that is associated
with ischemia/reperfusion stress to the myocardium.17 Indeed, we
observed that the abundance of plasma circulating exosomes and
their content of cardiovascular miRNAs were highly correlated
with high sensitive cardiac troponin T, the gold-standard biomarker
of myocardial injury.17 This suggests that the release of exosomes
from the heart is regulated in vivo. We reasoned that exosomes
released by the heart and large vessels could accumulate in the peri-
cardial space, which could gain new interest as a niche for cardiac
biomarker discovery. Moreover, PF exosomes could be involved in
yet unreported EV-based crosstalk between cells exposed directly
or indirectly to the PF.
RESULTS
Human PF Is Enriched with miRNAs of Potential Cardiovascular
Origin
In search for evidence in support of our hypothesis that the PF is
enriched with miRNAs released from the heart and thoracic vascula-
ture, under ethical approval, we obtained the PF, peripheral blood-
derived plasma, and leftover tissue samples of myocardium (right
atrial appendage) and vasculature (ascending thoracic aorta) from
surgical patients undergoing aortic valve replacement (AVR) (for
study population, see Table S1). An exploratory PCR-based miRNA
microarray (Exiqon) on non-pooled, randomly selected samples
of whole PF (n = 3) revealed the presence of several miRNAs in
the PF of the patients (see Table S2). Interestingly, several miRNAs
of putative cardiovascular origin appear to be relatively highly ex-
pressed (see red text in Table S2). Fifteen of these miRNAs were
rationally selected for further analyses, together with miR-208 (sup-
posedly enriched in cardiomyocytes) and the liver-enriched miR-122
(used as a “non-cardiovascular” control) (see Table S3 for the 16 car-
diovascular miRNAs that were selected for further investigation and
reporting the miRNA particulars). Working on surgical leftover sam-
ples, we validated that the 16 bona ﬁde cardiovascular miRNAs were
indeed well expressed in the myocardium and/or vasculature of the
patients. By contrast and as expected, miR-122 was poorly expressed
in the tissue samples (Figure S2). Next, by performing PCR for indi-
vidual miRNAs on matched PF and plasma samples, we obtained ev-
idence supporting the concept that the PF is enriched with miRNAs
released from cardiovascular tissues (Figure 1; Supporting Materials
and Methods). These data align with our hypothesis that the PF rep-
resents a liquid compartment in which expressional information and
executive command from the heart and thoracic vessels are released
in the form of miRNAs.
Human PF Contains Exosomes Carrying Cardiovascular
miRNAs
We reasoned that the cardiovascular miRNAs present in the PF could,
at least in part, be included in exosomal cargos. Nanosight LM10
nanoparticle tracking analyses (NTA) revealed the presence of exo-
some-sized (30–120 nm) particles in both the PF and plasma, which
we analyzed as a reference (Figures 2A and 2B; the rectangles sur-
round exosome-sized particles). Next, exosomes were enriched
from the PF and plasma. The quality of the exosome preparations
was validated by western blotting for a panel of exosomes antigens
(ALIX, CD63, FLOT1, and EPCAM) (Figure 2C) and by transmission
electron microscopy (TEM) using gold particles conjugated with an
anti-CD63 antibody (Figure 2D) to conﬁrm the exosome identity.
The miRNAs already detected in the total PF where also measurable
in the PF exosomes. Moreover, for the majority of the individual
miRNAs, the expressional differences appreciated comparing whole
PF versus whole plasma were conﬁrmed when looking at the exoso-
mal components of the two ﬂuids (Figure 3A). This set of results sug-
gests that miRNAs produced by cells of the heart and heart vessels are,
at least in part, transported to the PF via exosomes. Next, to investi-
gate if the miRNAs are differently distributed between the exosomal
and non-exosomal fractions of the PF, we calculated the PF exosome/
whole PF concentration ratios of the individual miRNAs. The PF
exosome/total PF ratios were highly variable between miRNAs (Fig-
ure 3B), thus suggesting (1) a non-random incorporation of the
miRNAs in the PF exosomes and/or (2) that miRNAs are released
by cells via different mechanisms.
PF Exosomes Contain the RISC Components AGO-2 and DICER
To establish if AGO-2-miRNA complexes were present in the PF
samples, AGO-2 immunoprecipitation (IP) was performed (Fig-
ure 4A) and followed by miRNA RT-qPCR analyses. The majority
of our miRNAs were found conjugated to AGO-2 (Figure 4B). The
relative expression of the individual miRNAs conjugated to AGO-2
was variable (Figure 4B), and it did not follow the same trends of
exosomal miRNA expression (Figure 3A). Interestingly, the majority
of studied miRNAs were co-expressed in exosomes and AGO-2
complexes, suggesting the possibility that PF exosomes contain
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AGO-miRNA complexes. In line with this, AGO-2 was detected (by
western blot analysis) in the PF exosome preparations (Figure 4C).
Moreover, AGO-2-IP of PF exosomes, followed by PCR for a
randomly selected subset of the miRNAs expressed in the AGO2
complexes, conﬁrmed the presence of AGO-2-miRNA complexes
in the exosomal compartment of human PF (Figure 4D). Also in
this case, the relative expression of the individual exosomal miRNAs
conjugated to AGO-2 was variable, with let-7b-5b appearing partic-
ularly enriched in the AGO-2 complex (Figure 4D). Dicer was also
present within the PF exosomes (Figure 4E). Similarly to PF, plasma
exosomes also contained both Dicer and AGO-2 (Supporting Mate-
rials and Methods). When the exosome membrane was not previ-
ously destroyed by sonication, the exosomal miRNAs (let-7b-5p
and miR-122) and proteins (DICER and AGO2) were resistant to
proteinase K (PK) and RNase A digestion (Figure S3). This favors
the hypothesis that the miRNAs, DICER and AGO-2 were indeed
encapsulated inside the exosomes, rather than being merely co-
precipitated with them. Taken together, the above data provide evi-
dence that exosomes contain miRNAs that are co-expressed and
possibly physically associated with the RISC. It is therefore possible
that exosomes deliver miRNAs together with a RISC machinery
ready to act in recipient cells, thus immediately eliciting expressional
changes commanding functional responses.
PF Exosomes Are Incorporated by Cultured ECs and Enhance
Their Angiogenic Capacity
To investigate whether the PF exosomes are functionally active, we
tested them on cultured ECs focusing on responses that are conducive
to angiogenesis. Patient-derived plasma exosomes were used for com-
parison. PF or plasma exosomes clusters, labeled with a green ﬂuores-
cent marker, were added to cultured ECs, and their internalization
was conﬁrmed by confocal microscopy 3D and reconstruction of
the confocal image z stacks (Figures 5A and S6A). Two negative con-
trols were included to conﬁrm the speciﬁcity of the exosome uptake
derived from the PF (Figure S4). Next, exosomes were studied in
cell biology assays developed on cells kept under hypoxia. In compar-
ison to the PBS control, PF-derived exosomes inhibited EC apoptosis
(Figure 5B) and increased EC proliferation (Figure 5C). Moreover,
the PF exosomes, in comparison to PBS control and PF-derived exo-
somes, were also able to promote the formation of capillary-like
cellular networks on Matrigel (Figures 5D, 5E, and S5), while the exo-
some-depleted PF fraction had no effect. Plasma exosomes did not
affect any of the tested EC functions (Figures S6B–S6E). Exosome
concentration-response curves conﬁrmed the inactivity of plasma
exosomes on ECs (Figures S6F and S6G) in the concentration range
whereas PF exosomes increased EC survival and proliferation (Fig-
ures S6H and S6I). We speculate that the differential behavior of
Figure 1. Human PF Is Enriched with MicroRNAs of Potential Cardiovascular Origin
The expression of selected microRNAs (miRNAs) was measured (RT-qPCR) in paired PF (black column) and peripheral plasma (gray column) samples. The PF/plasma
concentration ratios of individual miRNAs are plotted on the right side of the graphs. Exogenous spike-in cel-miR-39 was the normalizer. MiR-122-5p was used as a non-
cardiovascular control. N.D., not detectable. All values are mean + SEM. *p% 0.05, **p% 0.01, and ***p% 0.001 versus plasma (unpaired Student’s t test); n = 5–9.
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exosomes from PF and plasma might be in part related to differences
in their miRNA cargos.
The PF-Enriched let-7b-5p Is a Proangiogenic miRNA
Next, we questioned whether exosomal miRNAs contributed to the
angiogenic responses elicited by the PF exosomes. To answer this,
we focused on let-7b-5p, which was chosen because it was highly ex-
pressed in the PF exosomes (Figure 3A), including as conjugated with
AGO-2 (Figure 4D), and because other members of the Let-7 family
were known to stimulate angiogenesis.18,19 Expressional data were
validated using standard curves. In fact, we found that in comparison
with plasma, the whole PF contained higher let-7b-5p and lower miR-
122 copy numbers (Figures S7A and S7B). Moreover, we conﬁrmed
the presence of let-7b-5p in PF exosomes (Figure S7C). By transfect-
ing ECs with a let-7b-5p mimic, a let-7b-5p inhibitor, or their
respective controls (see Figure 6A for validation of the impact of
transfection on let-7b-5p in ECs), we demonstrated that let-7b-5p
promotes angiogenesis in vitro. In fact, increased let-7b-5p improved
capillary-like tube formation on Matrigel (Figure 6B, top), while let-
7b-5p inhibition produced the opposite effect (Figure 6B, bottom),
and decreased EC proliferation (Figure 6D, right). By contrast, let-
7b-5p did not affect the survival of cultured ECs (Figure 6C). We
also determined whether the expression of three previously validated
direct target genes of let-7b-5p was affected by forcing let-7b-5p
expressional changes in ECs. Increased let-7b-5p reduced the
mRNA expression of the antiangiogenic TGFBR1 only20,21 (Fig-
ure 6E), leaving unchanged the other two potential target genes,
LOX-1 and CASPASE 3 (Figures S8A and S8B). Therefore, the latter
were not taken forward for further analyses.
The Angiogenic Action of PF Exosomes Is Partially Mediated by
let-7b-5p
We next interrogated the possibility that let-7b-5p could be trans-
ferred from PF exosomes to ECs and the expressional and functional
impact of exosomal let-7b-5p uptake by recipient ECs. For these ex-
periments, we adopted a model in which the endogenous expression
of miRNAs is reduced. It was previously reported that miRNA
biogenesis, and hence intracellular miRNA levels, are decreased after
DICER silencing in cultured ECs. Moreover, DICER knockdown
(KD) reportedly impairs the angiogenic capacity of cultured ECs.22
We initially conﬁrmed that DICER KD resulted in reduced DICER
gene and protein expression (Figures S9A and S9B) and impaired
the angiogenic potential of ECs (Figures S9C and S9D). Moreover,
as expected, DICER KD reduced let-7b-5p expression (Figure 7A).
Next, ECs with either DICER KD or a preserved DICER expression
were stimulated with our PF exosomes. Treatment with PF exosomes
Figure 2. PF Contains Nanoparticles of the Size and Antigenic Profile of Exosomes
(A and B) Nanoparticle tracking analysis (NTA) was used to quantify the concentration (A) and size distribution (B) of particles in the total PF and plasma. The dotted rectangles
evidence exosome-sized vesicles (30–120 nm). (C and D) PF and plasma exosome preparations were positive for the exosomal markers ALIX, FLOT1, EpCAM and CD63.
Transmission electron microscopy (TEM) using a gold particle-conjugated anti-CD63 antibody further confirmed exosome identity. In the bottom right corner of (D), next to
CD63-immunoreactive exosomes, is shown a larger unreactive cytoplasmic vesicle as negative control (the scale bar represents 100 nm). Unpaired two-tailed Student’s t test
was applied. All values are mean + SEM; n = 5.
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restored intracellular let-7b-5p expression, which had been compro-
mised byDICER KD (Figure 7A), thus supporting the hypothesis that
this proangiogenic miRNA is transferred from the PF exosomes to the
recipient ECs. In line with the hypothesis that the let-7b-5p delivered
from PF exosomes into ECs is functionally active, ECs treated with PF
exosomes responded with a decreased mRNA expression of the
miRNA target gene TGFBR1 (Figure 7B). In ECs with DICER KD,
treatment with PF exosomes was additionally able to restore DICER
expression at protein (Figure S10A), but not mRNA, levels (data not
shown). This, together with the aforementioned ﬁnding of DICER
presence in the exosomes (Figure 4E), further suggests that PF exo-
somes pass on miRNAs and other components of the RISC machin-
ery to recipient cells. Finally, and in line with their induced let-7b-5p
and TGFBR1 expressional changes, PF exosomes restored the angio-
genic capacity of DICER KO-ECs (Figures 7C and 7D). To further
investigate the transfer of PF exosomal let-7b-5p to ECs and its func-
tional consequence, we preventively suppressed let-7b-5p inside the
exosomes. The reduction of exosomal let-7b-5p in PF exosomes
transfected with the miRNA inhibitor was conﬁrmed by qPCR (Fig-
ure S10B). Moreover, the PF let-7b-5p KD-exosomes could not (1)
restore let-7b-5p levels (Figure 7A), (2) decrease TGFBR1 expression
(Figure 7B), or (3) improve angiogenesis (Figures 7C and 7D) in
recipient DICER-KD ECs. Taken together, these data support the hy-
pothesis that PF exosomes are functionally active and stimulate
angiogenesis, at least in part, via the passage of the proangiogenic
let-7b-5p to ECs.
PF-Derived Exosomes Promote Post-ischemic Angiogenesis
and Blood Flow Recovery
We investigated whether the angiogenic capacity shown by PF exo-
somes in vitro may translate into improvement of angiogenesis and
blood ﬂow recovery in vivo. The therapeutic potential of PF exosomes
was studied in a mouse model of ischemia, in which local stimulation
of angiogenesis represents a possibility to improve tissue perfusion.
As controls, we used PBS and plasma exosomes, which we had proved
unable to induce in vitro angiogenesis (Figures S6B–S6G). Mice with
surgically induced unilateral limb ischemia were injected with either
PBS or exosomes (100 mg/mouse) directly into their ischemic
adductor muscles. Compared with PBS, at 7 days from delivery, the
PF-derived exosomes improved post-ischemic blood ﬂow recovery
Figure 3. Human PF Exosomes Carry Cardiovascular miRNAs
(A) miRNA level normalized to the spike-in cel-miR-39. (B) PF exosome/total PF ratios calculated for each miRNA. All values are mean + SEM. *p% 0.05, **p% 0.01, and
***p% 0.001 versus plasma (unpaired Student’s t test); n = 5.
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(Figures 8A and 8B), reduced the incidence of ischemia-induced toe
necrosis (Figure 8C), and improved capillary density in ischemic
muscles (Figures 8D and 8E). The positive impact of PF exosomes
on blood ﬂow recovery was not sustained over time (data not shown).
Plasma exosomes were not able to reproduce any of the above thera-
peutic beneﬁts (Figures 8A–8E). Importantly, after transfer of PF exo-
somes into ischemic limbmuscles, there was a trend toward increased
let-7b-5p expression (p = 0.18; Figure 8F) and a signiﬁcant decrease in
Tgfbr1 expression (p < 0.05; Figure 8G), which could be explained
by an ampliﬁed functional response at the target gene level of the
PF exosome-mediated delivery of active let-7b-5p.
In conclusion, the exosomes contained in human PF have shown
the capacity to induce vascular protective and reparative functions
in vitro and in vivo, suggesting their importance in the context of car-
diovascular physiopathology.
DISCUSSION
Vascular cells, cardiomyocytes, cardiac ﬁbroblasts, and cardiac pro-
genitor cells reportedly secrete miRNA-containing exosomes in cul-
ture systems.23 Functional studies focusing on exosomes in human
biological ﬂuids are still lacking. Such studies are of importance to
characterize the relevance of exosome-based communication in hu-
man pathophysiology. We have reported the vascular regenerative
potential of exosomes prepared from biological ﬂuids collected
from cardiovascular patients.
Exosomes produced from stem and progenitor cells, including the
ones isolated from cultured adult cardiac progenitor cells (CPCs),
which have been claimed to reside in the human heart and contribute
to myocardial regeneration, have shown proangiogenic effects.24,25
However, the in vivo abundance and physiological relevance of
CPCs are currently intensively questioned,26,27 thus discouraging
the speculation that exosomes released in vivo by CPCs play a major
role in heart homeostasis. Stem and progenitor cells still represent
hope for vascular regeneration. In a seminal paper, Sahoo et al.28
showed that bone marrow mononuclear cell (MNC)-derived CD34-
positive cells promote therapeutic angiogenesis in vitro and in vivo
via paracrine actions that can be recapitulated by their exosomes,
but not by exosomes from MNCs. Later studies have expanded on
this to recognize that proangiogenic exosomes are released in culture
by the different types of progenitor cells so far trialled in patients with
heart ischemia.13 These ﬁndings open new exciting therapeutic ave-
nues but do not address the contribution of endogenous exosomes
to cardiovascular physiopathology. Additionally, not all exosomes
stimulate angiogenesis. As an example, exosomes from diabetic cardi-
omyocytes reportedly inhibited endothelial cell (EC) survival and
angiogenesis by the transfer of miRNA-320.29
The angiogenic response to PF exosomes described in our study
appears “speciﬁc” to PF-derived exosomes because it could not be re-
produced using exosomes prepared from the plasma of the same pa-
tients. Evidence from the literature suggests that peripheral plasma
Figure 4. PF Exosomes Contain DICER and AGO-2 Protein
(A) Validation by immunoblotting of AGO-2 immunoprecipitation (IP) performed on human PF samples using AGO-2 antibody. Mouse non-specific IgG antibody was used as
control for the IP. ECs were used as positive control (CTRL). (B) The miRNA expression after AGO-2 IP is presented as fold enrichment relative to IgG; mean + SEM; n = 5. (C)
AGO-2 in exosomes enriched from PF samples (representative western blot images). (D) AGO-2 IP was performed on exosomes enriched from PF samples. miRNA
expression is expressed as fold enrichment in the AGO-2 IP relative to IgG; mean + SEM; n = 2. (E) Representative western blot images of DICER protein incorporated in the
exosomes.
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exosomes could elicit different cardioprotective functions.15 Alterna-
tively, the type of patients we have studied could present with
alterations in their plasma exosomes. This study was conducted on
patients with aortic stenosis undergoing aortic valve replacement.
These patients are afﬂicted by left ventricular hypertrophy. Cardiac
hypertrophy is associated with complex multicellular alterations,
including hypertrophy, ﬁbrosis, and inﬂammation.30 These actions
are brought about by cardiac and non-cardiac cells through a variety
of cell-to-cell communication pathways.30 In particular, during car-
diac hypertrophy, the contractile function of the myocardium must
be sustained by phenotypic changes of the capillary ECs leading to
angiogenesis. Previous studies identiﬁed that proangiogenic factors
released by cardiac myocytes sustain the capillary density and the ox-
ygen supply.31,32 Our data are in line with the new paradigm that PF
exosomes and their miRNAs contribute to modulating the growth of
new capillary vessels, thus protecting the heart from an accelerated
failure. In support of this hypothesis, we found that the PF exosomes
isolated from cardiovascular patients promote angiogenesis in vitro
and in vivo. However, it is also possible that compared with healthy
controls, PF exosomes from AVR patients have a reduced altered
proangiogenic potential. This question could not be investigated in
our human studies and will need to be deferred to work on suitable
animal models.
We have mechanistically implicated a newly deﬁned pro-angiogenic
miRNA, let-7b-5p, in the proangiogenic responses to PF exosomes.
However, in addition to let-7b-5p and other proangiogenic miRNAs,
PF exosomes also contain several anti-angiogenic miRNAs (Table
S3). The overall proangiogenic responses to the PF exosomes might
be dictated by a functional prevalence of proangiogenic miRNAs
that are simultaneously transferred by the same nanoparticles. How-
ever we cannot discount the possibility that anti-angiogenic miRNAs
are enriched in a subset of exosomes that are taken up with reduced
efﬁciency by the ECs. Moreover, the expression of individual miRNAs
in a cell context and possibly in the exosomes does not always reﬂect
the level of the individual miRNAs binding to AGO-2 and hence their
Figure 5. PF-Derived Exosomes Are Incorporated by Cultured ECs and Enhance Their Angiogenic Capacity
(A) PF-derived exosomes (10 mg/ml) stained using carboxyfluorescein succinimidyl ester (CFSE, in green) were incubated with ECs for 24 hr. Next, cells were stained with
phalloidin (red) and DAPI (blue) (the scale bar represents 25 mm). (B and C) Column graphs show (B) EC apoptosis (measured by caspase-3 activity assay) and (C) EC
proliferation (measured by BrdU incorporation) after treatment with 10 mg/ml of either PF- exosomes (black columns) or exosome-depleted PF (gray columns). PBSwas used
as an additional control (open columns); n = 7. (D) Photomicrographs show endothelial network formation on Matrigel (the scale bar represents 200 mm); 2.5magnification.
(E) Bar graphs showMatrigel assay quantification (total length of EC tube-like structures). All values are mean + SEM. *p% 0.05 and ***p% 0.001 versus PBS, # # #p% 0.001
versus PF exosome-free (one-way ANOVA, Dunnett’s post hoc test); n = 6.
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functionality. In fact, it is emerging that the association between
miRNAs and the RISC complex is a regulated process. As an example,
Krell et al.33 showed that following DNA damage, P53 interacts with
AGO-2 to induce or reduce AGO-2’s association with subsets of
miRNAs, including multiple let-7 family members.
Our study provides the ﬁrst evidence that the pericardial space might
represent a special compartment, in which functional forms of
miRNAs that are released from the heart are enriched in comparison
with the peripheral circulation. Because of their resilience to degrada-
tion in the extracellular space, miRNAs have been widely consid-
ered as new potential clinical biomarkers. Pioneer miRNA-oriented
biomarker discovery studies have been developed by measuring
miRNAs in the peripheral circulation. However, the emerging evi-
dence for the multi-cellular and multi-tissue expression of virtually
any of the known miRNAs, together with the understanding that
several processes (release from different cells and organs, potential
uptake from the circulation into other tissues, urinary excretion,
etc.) dictate the miRNA concentration in the peripheral blood,
diminish the potential value of miRNAs as peripheral blood circu-
lating biomarkers. We propose that miRNA expression in the PF is
more indicative of cardiac miRNA expression and secretion. In de-
fense of our hypothesis, we have shown increased cardiovascular
miRNA expression in the total PF and in PF-derived exosomes in
comparison with the corresponding plasma counterparts. Exosomes
have been already suggested as “liquid biopsies.”34 Our study stimu-
lates the original hypothesis that obtaining such liquid biopsies out of
the PF (when accessible) rather than from the peripheral blood could
Figure 6. The PF-Enriched let-7b-5p Is a Proangiogenic MicroRNA
(A) ECs were transfected with either a let-7b-5p mimic (right) or a let-7b-5p inhibitor (left). The random sequence anti-miR miRNA inhibitor (scramble) was used as control.
Efficiency of let-7b-5p transfection was assessed by qPCR using U6 as a normalizer. (B) Matrigel assay photomicrograph (the scale bar represents 100 mm) and quantification
(total length of tube-like structures), 5 magnification. (C and D) Caspase activity (C) and BrdU incorporation (D) of ECs transfected as previously described. (E) Relative
expression of the let-7b-5p direct target gene TGFBR1 (measured by PCR using ubiquitin C [UBC] as normalizer). All values are mean + SEM. *p% 0.05, **p% 0.01, and
***p% 0.001 versus the respective scramble control (unpaired Student’s t test); n = 4.
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increase the diagnostic and prognostic power of exosomal bio-
markers. Speciﬁcally designed clinical studies are necessary to validate
the biomarker value of PF miRNAs.
In this study, we have used human exosomes in immunocompetent
mice. It was already published that exosomes derived from human
progenitor cells can induce therapeutic effects in immunocompetent
small35 and large36 animal models. Nonetheless, we cannot discount
the possibility that an immune response could have reduced the ther-
apeutic efﬁcacy of the exosomes. In line with this possibility, the pos-
itive impact of PF exosomes on blood ﬂow recovery was not sustained
over time. On the other hand, exosomes have been suggested to be
able to modulate immunity.37 Given the increasingly recognized
importance of the crosstalk between the immune and cardiovascular
systems in health and disease, we would not exclude that exosomes
could inﬂuence cardiovascular responses partly by modulating the
immune system.
The interest in exosomes as new therapeutic tools is growing.28,38 The
production of exosomes from patients’ own cells and biological ﬂuids
could represent a new avenue for autologous regenerative therapies.
Additionally, careful characterization of endogenous exosomes with
proven therapeutic capacity should help with the future fabrication
of nature-inspired artiﬁcial vesicles carrying a deﬁned therapeutic
cargo, which could represent an option for developing exosomes
into off-the-shelf therapeutic products to be used in different cardiac
and non-cardiac conditions.
Study Limitations
First, we have conducted an exploratory study using anonymized sur-
gical leftover material from patients undergoing AVR. As such, our
study has been able to provide the ﬁrst characterization of the PF
exosomal compartment but not to investigate its biomarker value.
Prospective studies collecting clinical samples and data (at baseline
and follow-up) from surgical and non-surgical patients are next
required. Interestingly, the PF represents a leftover material from
most cardiac surgeries and is also sampled for diagnostic purposes
in non-surgical patients.39,40 However, this ﬂuid is not always acces-
sible, thus limiting the translational potential to particular clinical
conditions and to restricted time windows. Second, we have focused
on the proangiogenic actions elicited by PF exosomes. We already
know that PF exosomes are taken up by additional types of heart cells
Figure 7. Let-7b-5p Underpins the Angiogenic Action of PF Exosomes
ECs were transfected with either a sequence that exhibits no homology to the human genome (scramble) or DICER silencing RNA (siRNA) to knock down (KD) DICER for
24 hr, before being treated with either naive PF exosomes or PF exosomes previously depleted of their let-7b-5p content (exosome let-7b-5p KD). (A and B) Columns graphs
show the relative expression of (A) let-7b-5p and (B) TGFBR1 in the exosome recipient ECs and untreated cell controls; n = 4. (C) Photomicrographs (the scale bar represents
100 mm) and (D) quantification of Matrigel assays performed using ECs treated as previously indicated; n = 5; 2.5magnification. All values are mean + SEM. xp% 0.05 and
xxxp% 0.001 versus scramble, *p% 0.05 and ***p% 0.001 versus DICER KD, #p% 0.05 and ##p% 0.01 DICER KD treated with naive PF exosomes (one-way ANOVA,
Tukey’s post hoc test).
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(C.B., unpublished data) and further studies will be necessary to
disclose their full spectrum of actions. Third, we have concentrated
our attention on miRNAs. However, other molecular components
of the exosome cargo could contribute to the angiogenic effects of
exosomes as well as representing potential biomarkers. Fourth, and
conversely, extracellular miRNAs are not only contained in exosomes,
and the fundamental and translational importance of miRNAs car-
ried via different transporter systems is not to be neglected.
MATERIALS AND METHODS
Clinical Sample Collection and Processing
The collection and use of clinical samples for research complied with
the ethical principles stated in the “Declaration of Helsinki” and the
Human Tissue Act and were covered by ethical approvals from the
UK National Research Ethic Service NRES (Research Ethic Commit-
tee –REC- references 13/OL/1687 and 10/HO107/63). We collected
leftover samples from patients undergoing aortic valve replacement
(AVR). The total PF volume was collected immediately after opening
of the pericardium using a 20 mL syringe and transported to the lab-
oratory in a sterile 50 mL container. Peripheral blood was collected
from an arterial line in citrate-containing vacutainers (BD). Samples
of right atrial appendage (RAA) were collected just before cannula-
tion of the right atrium, and samples of ascending thoracic aorta
were collected from excessive tissue on closure of the aortotomy.
These were immediately placed in RNA Later stabilizing solution
(Thermo Fisher Scientiﬁc) and stored at 80C until processed.
Blood and PF were processed immediately after collection, as follows.
To obtain plasma, the citrate-containing vacutainers were centrifuged
at 1,500  g, 4C for 15 min, and the supernatant was collected. The
supernatant underwent further centrifugation at 13,500  g, room
temperature (RT), for 5 min to deplete the sample of miRNA-rich
platelets. The platelet-free ﬂuid was centrifuged at 13,500  g, RT,
Figure 8. PF-Derived Exosomes Promote Reparative Angiogenesis and Blood Flow Recovery in a Mouse Limb Ischemia Model
Unilateral limb ischemia was surgically induced in CD1 mice. Next, mice were injected in their ischemic adductor muscle with 100 mg of exosomes from either the PF or
plasma. A control group received PBS. (A) Representative color laser Doppler images of lower limb perfusion at baseline and at day 7 post-ischemia. (B) The blood flow
recovery to the ischemic foot was calculated as percentage versus the contralateral foot (n = 20mice/group). (C) Percentage of necrotic toes in animals treated with PBS, PF,
or plasma-derived exosomes. **p < 0.01 versus PBS. (D) Representative immunofluorescent images of ischemic adductor muscle sections after staining with green fluo-
rescent isolectin-B4. (E) Capillary densities in the ischemic adductors at 7 days post-ischemia induction (n = 8 per group). Average capillary density was determined from eight
randomly selected high-power fields (magnification 20). ##p < 0.01 versus PBS. (F and G) Let-7b-5p (F) and Tgfbr1 (G) expression in ischemic mouse adductors injected
with PF exosomes or PBS (control); n = 5. *p% 0.05 versus PBS. All values are mean + SEM.
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for 5 min to remove any remaining of cells. The ﬁnal platelet-
poor plasma, PF and tissue samples were stored at 80C until
required.
RNA Extraction and Quantitative Real-Time Analysis
Total RNA was extracted using the miRNeasy kit (Qiagen), according
to the manufacturer’s instructions. For RNA extraction from solid tis-
sues (ascending thoracic aorta and right atrial appendage), about
50 mg of tissue was ﬁrst homogenized in 1 mL QIAzol (Qiagen) in
a gentleMACS M tube using the gentleMACS dissociator (both
from Miltenyi Biotec). For RNA extraction from PF and plasma,
200 ml of sample was used with 1 mL of QIAzol. A synthetic analog
of the non-human Caenorhabditis elegans microRNA-39 (cel-
miRNA-39; Qiagen) was spiked in (10 ml of a 5 fmol/ml stock) to
normalize RNA extraction efﬁciency. Reverse transcription of indi-
vidual miRNAs was performed using the TaqMan miRNA Reverse
Transcription Kit and miRNA-speciﬁc stem-loop primers (see Table
S3; Thermo Fisher Scientiﬁc). qPCR was performed in triplicate using
2x Universal PCR Master Mix with No AmpErase UNG (Thermo
Fisher Scientiﬁc) using the QuantStudio 6 Flex Real-Time PCR Sys-
tem (Thermo Fisher Scientiﬁc). miRNA expression was normalized
with either cel-miRNA-39 (for biological ﬂuids) or with the small nu-
clear U6 small nuclear RNA (snRNA) (ID: 001973) (for solid tissues).
For mRNA analysis, cDNA obtained using the High-Capacity RNA-
to-cDNA Kit (Thermo Fisher Scientiﬁc) was ampliﬁed by real-time
qPCR. TaqMan Gene Expression Assays (Thermo Fisher Scientiﬁc)
and 2x Universal PCRMaster Mix with No AmpErase UNG (Thermo
Fisher Scientiﬁc) were used to analyze the gene expression of TGFBR1
(ID: Hs00610320_m1), CASPASE3 (ID: Hs00234387_m1), LOX (ID:
Hs00942480_m1), and UBC (ID: Hs00824723_m1) (all from Thermo
Fisher Scientiﬁc). Real-time quantiﬁcation to measure gene expres-
sion for human DICER and mouse TGFBR1 was performed using
Power SYBR Green PCR Master Mix (Thermo Fisher Scientiﬁc)
and normalized against human or mouse GAPDH.
Primers used were as follows:
Human DICER Fw: ATTCTAGTGCAGGTTTTTCAAGCC,
Human DICER Rv: ACCTCAGATTCCACACTTTCCTG,
Human GAPDH Fw: AGCCGCATCTTCTTTTGCGT,
Human GAPDH Rv: TGACGAACATGGGGCATCA,
Mouse TGFBR1 Fw: AGAGCTGTGAGGCCTTGAGA
Mouse TGFBR1 Rv: TTGATGCCTTCCTGTTGGCT
Mouse GAPDH Fw: TGTGAACGGATTTGGCCGTA
Mouse GAPDH Rv: ACTGTGCCGTTGAATTTGCC.
For absolute miRNA quantiﬁcation, the Ct value obtained from a
dilution series (ranging from 100 nM down to 10 fM) of chemically
synthesized RNA oligonucleotides corresponding to the mature
miRNA sequence of let-7b-5p (UGAGGUAGUAGGUUGUGUG
GUU) and miRNA-122-5p (UGGAGUGUGACAAUGGUGUUUG)
were used to generate standard curves (both were purchased from
Sigma).
miRNA Array on Human Pericardial Fluid
Total RNA was converted to cDNA using a reverse transcription kit
(Universal cDNA Synthesis Kit, Exiqon). Three (unpooled) PF sam-
ples of the AVR surgical patient group were randomly selected to be
run in a PCR-based miRNA array enabling the proﬁling of 752 hu-
man miRNAs (miRNACURY LNA microRNA PCR human panels
I and II; version 3, Exiqon). The miRNA array plates were run using
a LightCycler 480 (Roche).
miRNA Array Bioinformatics Analyses
For the bioinformatics analyses, the processing settings were as
follows: (1) detection scoring: miRNAs not detectable in all three
samples or CtR 37 in at least two patients were not considered for
future calculations; (2) the average of inter-plate calibrator (UniSp3
IPC) was calculated for each run (representing one sample), and
the median was subtracted from eachmiRNA’s Ct; and (3) expression
of each miRNA was derived using the 2DDCT method.41 On the basis
of these criteria, array data were inspected using the NormFinder
algorithm to assess the variance in expression levels.42 The best
normalizer was found to be the average of assays detected in all three
AVR samples; therefore this was used to normalize the array. Data are
available at Gene Expression Omnibus (GEO: GSE80577).
PF and Plasma Nanoparticle Profiling
EVs present in whole plasma or PF were characterized using Nano-
particle Tracking Analysis (NTA). One microliter of sample was
diluted in sterile water to obtain a suitable concentration to be read,
according to the manufacturer’s guidelines. The sample was passed
through the ﬂow cell. Once the temperature of the ﬂow cell had
stabilized at 25C, six 30 s videos of each sample were taken with a
high-resolution camera, with a 1 s pause between each. The videos
were then processed by Nanoparticle Tracking Analysis software
(version 2.3), giving the concentration of particles per ml for each
nanometer size. The ﬁnal data for each sample is an average of the
data from six videos.
Exosome Enrichment from the PF and Plasma
Exosomes were enriched from 250 ml of PF and plasma using the
ExoQuick kit (System Biosciences). Thrombin (2.5 ml) (500 U/mL,
System Biosciences) per 250 ml plasma was added to remove the ﬁbrin
proteins. The samples were incubated at RT for 15 min while mixing,
then centrifuged at 10,000 g for 5 min at RT. PF and ﬁbrin-depleted
plasma were then ﬁltered through a sterile 0.22 mm ﬁlter (Merck
Millipore) into a fresh tube, and 75 ml ExoQuick solution was added.
The samples were incubated for 30 min at 4C, then centrifuged for
30 min at 1,500  g and 4C. The supernatant was removed, and
following an additional centrifugation of the sample at 1,500  g
for 5 min at 4C, the ﬂuid was taken off and the pellet was re-sus-
pended in 100 ml of sterile PBS. At the end of the process, the presence
of exosomes in the preparation was conﬁrmed by NTA, electron mi-
croscopy (see below) and western blotting. Protein concentrations
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were determined using Micro BCA protein assay (Thermo Fisher Sci-
entiﬁc), and speciﬁed exosome doses used in experiments are based
on these. miRNAs from exosomes were isolated using themiRNAeasy
kit (Qiagen) (see above).
Treatment of Exosomes with Proteinase K and RNase A
For this assay, exosomes obtained according to our method (see
above) were treated as previously described.43 Isolated exosomes
were incubated with proteinase K (50 mg/ml; Sigma) for 10 min at
37C, before 5 mM phenulmethulsulfonyl ﬂuoride (PMSF; Sigma)
was added for 10 min at room temperature to inhibit the proteinase
K (PK) activity. After the PK inactivation, the samples were incubated
with 100 mg/ml RNase A (Thermo Fisher Scientiﬁc) for 20 min
at 37C to degrade unprotected RNA, followed by incubation with
RiboLock RNase Inhibitor (Thermo Fisher Scientiﬁc). Finally protein
or RNA was extracted as described earlier. As control samples we
included (1) sonicated exosomes followed by treatment with PK
and RNase A or (2) exosomes treated with PBS added instead of
PK and RNase A.
Electron Microscopy
For morphological studies, each formvar-coated grid was positioned
on top of a 5 ml droplet of the pellet containing exosomes, previously
ﬁxed for two hours at 4C in Karnovsky ﬁxative (2% formaldehyde +
2% glutaraldehyde) for 60 min. Afterward, the grid was sequentially
positioned on three drops of 0.05 M, pH 7.3 cacodylate buffer for
5 min each. For ultrastructural immunocytochemical study, each for-
mvar-coated grid was positioned on the top of a 5 ml drop of the pellet
containing exosomes previously ﬁxed for 2 hr at 4C in modiﬁed Kar-
novsky ﬁxative (2% formaldehyde + 0.5% glutaraldehyde) for 60 min.
The grid was then put on three drops of 0.05 M, pH 7.3 cacodylate
buffer for 5 min each, on 2% formaldehyde for 10 min, on three drops
of 0.05 M, pH 7.3 cacodylate buffer for 5 min each, on the antibody
anti-CD63 (ab23792; Abcam) diluted 1:20 for 60 min, on three drops
of 1% BSA in 0.05M, pH 7.4 Tris buffered saline buffer for 5min each,
on the gold-tagged anti-mouse antibody (Jackson Immunoresearch)
diluted 1:20 for 60 min, and on three drops of 0.05 M, pH 7.4 Tris
buffered saline buffer for 5 min each. Next, both for morphological
and for immunocytochemical study, the grids were placed on a
drop of 2% glutaraldehyde for 10 min, then on three drops of distilled
water for 5 min each, on 5% uranyl acetate for 3 min, and ﬁnally on
0.013% methyl cellulose/0.04% uranyl acetate for 10 min on ice
(Lasser). Between each transfer, the excess liquid was removed by
holding an absorbing paper close to the side of the grid.
PF Exosome Incorporation by ECs
PF-derived exosomes were labeled using Exo-Glow based on carbox-
yﬂuorescein succinimidyl diacetate ester (CFSE) chemistry (System
Biosciences) according to the manufacturer’s recommendations. Hu-
man umbilical vein ECs (HUVECs) (Lonza) were seeded at a density
of 5  104 cells/well on a 24-well plate coverslip, and 10 mg/ml of
labeled PF-derived exosomes were added to target ECs in culture
for 24 hr at 37C. Cells were washed twice with PBS and ﬁxed with
4% buffered PFA (Sigma) in PBS for 20 min at RT. Nuclei were
stained by DAPI staining while actin ﬁlaments were labeled using
Rhodamine Phalloidin (Thermo Fisher Scientiﬁc). To assess the up-
take of exosomes by ECs, confocal images were acquired with a Leica
SP5-AOBS confocal laser scanning microscope attached to a Leica
DM I6000 inverted epiﬂuorescence microscope. All images were
collected using a 63 NA 1.4 oil immersion lens objective. The exci-
tation signals for Exo-Glow and Rhodamine Phalloidin were 494 and
540 nm, respectively. The ﬂuorescence emitted from the cells was re-
corded at 521 nm for Exo-Glow and 565 nm for Rhodamine Phalloi-
din. In all cases, z-stack images were obtained covering the entire
cell volume. Three-dimensional reconstruction of the confocal
image z stacks conﬁrmed the cytoplasmatic localization of internal-
ized exosomes.
Cell Culture and Cell Biology
HUVECs (Lonza) were grown in endothelial cell basal medium,
EBM-2 (Lonza), with the addition of 2% FBS and SingleQuots Kit
(EGM-2 medium; Lonza) at 37C with 5% CO2. After the ﬁrst expan-
sion, cells were then grown in EGM-2 medium using 2% exosome-
depleted FBS (System Biosciences). To mimic ischemia in vitro,
ECs were exposed to hypoxia (1% pO2) for 24 hr followed by treat-
ment with different concentrations of PF/plasma-derived exosomes
or exosome-depleted PF/plasma for 24 hr. HUVECs were used be-
tween passages 2 and 6.
Evaluation of Apoptosis and BrdU Incorporation in ECs
HUVECs were seeded in 96-well plates (5  103/well) and treated
with 5, 10, or 20 mg/ml of PF exosomes or the same concentrations
of exosome-depleted PF for 24 hr in hypoxia (1% pO2). The medium
was then replaced with a complete medium with supplemental BrdU
(10 mM) for 24 hr. BrdU incorporation was measured using the BrdU
ELISA assay kit (Roche). Caspase-3/7 activity was measured at 24 hr
using a luminescent cell death detection kit according to the manu-
facturer’s instructions (Caspase-GLO assay; Promega).
In Vitro Angiogenesis
HUVECs were seeded in 6-well plates (2 105/well) and treated with
10 mg/ml of PF/plasma exosomes or exosome-depleted PF/plasma for
24 hr in hypoxia, then detached using Accutase (Innovative Cell
Technologies) and plated (104/well) in a ﬂat-bottom 96-well plate
or m-Slide Angiogenesis (Ibidi), coated with Growth Factor Reduced
Matrigel (Corning). FormirVana miRNAmimic ormirVana miRNA
inhibitor experiments, HUVECs were seeded at a concentration of
7  103/well. After 6 hr, HUVECs were stained with Calcein AM
(Biotium), and network formation was quantiﬁed by calculating the
length of the cellular network on images captured using an objective
magniﬁcation of 5 or by Angiogenesis Analyzer for ImageJ using a
ﬂuorescence objective magniﬁcation of 2.5.
HUVEC and Exosome Transfection
Lipofectamine RNAiMAX (Thermo Fisher Scientiﬁc) was used to
transfect HUVECs with scramble siRNA (75 nM total), siRNAs
against DICER (25 nM for each siRNA, 75 nM total), mirVana
miRNAmimic let-7b-5p (12.5 nM, MC11050), andmirVana miRNA
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inhibitor let-7b-5p (12.5 nM, MH11050), Pre-miR Negative Control
(12.5 nM, AM17120) and Anti-miR Negative Control (12.5 nM,
AM17011) (all from Thermo Fisher Scientiﬁc), according to the man-
ufacturer’s instructions. Published sequences22,44 of siRNA against
DICER and scramble were used (all purchased from Qiagen).
Exosomes were transfected withmirVana miRNA inhibitor let-7b-5p
(MH11050; Thermo Fisher Scientiﬁc) using Exo-Fect Exosome
Transfection Kit (System Biosciences) and following the guideline’s
recommendations.
In Vivo Experiments
The experiments involving mice were performed in accordance with
the Animal (Scientiﬁc Procedures) Act (UK) of 1986 prepared by the
Institute of Laboratory Animal Resources and under the auspices
of UK Home Ofﬁce Project and personal licenses. Eight-week-old
CD1 male mice underwent surgical induction of unilateral limb
ischemia (LI) by performing occlusion of the left femoral artery, as
we reported previously.45 Immediately after LI induction, mice
received 100 mg of exosomes derived from either PF or plasma into
the ischemic adductor muscle, while a control group received PBS
(n = 20 mice/group). The superﬁcial blood ﬂow to both ischemic
and non-ischemic feet was measured using a high-resolution laser co-
lor Doppler imaging system (Moor LDI2, Moor Instruments) at days
0 and 7 after induction of limb ischemia. Blood ﬂow recovery was
calculated as a percentage versus day 0 of the control PBS. At day
7, mice under terminal anesthesia were perfusion-ﬁxed successively
with 6 mL of 0.05 M EDTA and 10 mL of 10% formalin solution.
Limb muscles were harvested and stored in PFA 4% overnight at
room temperature then washed with PBS and ﬁnally treated with
30% sucrose overnight at 4C. The tissue samples were then
embedded in optical cutting temperature (OCT) compound and
stored at 80C until histological and immunohistochemical ana-
lyses. A second set of mice (n = 12 per group) were made ischemic
and immediately treated with either PF exosomes or PBS as described
above. Doppler analyses were performed at baseline, 7, 14, and
21 days post-ischemia induction. For molecular biology analyses,
mice were sacriﬁced at 3 days after surgery, and the ischemic abductor
muscles were dissected and snap-frozen in liquid nitrogen. Total
RNA was extracted from snap-frozen muscles as described above.
Histology
The experiments involving mice were performed in accordance with
the Animal (Scientiﬁc Procedures) Act (UK) 1986 prepared by the
Institute of Laboratory Animal Resources and covered under the
UK Home Ofﬁce Project license PPL/30/3373. The functional
impact of PF- and plasma-derived exosomes on treatment of CD1-
ischemic mice was assessed by measuring capillary density in the
adductor muscle. Eight-micrometer-thick muscle sections were
stained using biotin-conjugated Isolectin B4 (from Griffonia Simpli-
cifolia; Thermo Fisher Scientiﬁc) and streptavidin-conjugated Alexa
488 (Thermo Fisher Scientiﬁc) antibodies to detect capillaries. Nuclei
were stained with DAPI (40,6-diamidino-2-phenylindole). The slides
were mounted using Fluoromount-G (eBioscience). The relative
number of positive cells was counted in eight randomly selected
high-power ﬁelds (magniﬁcation 20) using a Zeiss inverted ﬂuores-
cence microscope. Analyses were performed using muscles from eight
mice per group. Capillary density was expressed as number per square
millimeter.
Immunoprecipitation and Western Blot Analysis
One hundred microliters of Magna Bind goat anti-mouse IgG Mag-
netic Beads (Thermo Fisher Scientiﬁc) were washed three times
with PBS solution (200 ml) and incubated with 10 mg of mouse mono-
clonal anti-AGO2 (ab57113, Abcam) or mouse IgG (Santa Cruz
Biotechnology) antibodies for 2 hr at 4C. The pre-incubated beads
and antibodies were then added to 200 mL of PF and incubated over-
night at 4C. Beads were washed 3 times with 1% Nonidet P-40 buffer
and re-suspended in 200 mL of PBS. One half of each sample was
eluted in loading buffer followed by western blot analysis. Protein ex-
tracted from HUVECs was used as a positive control. The other half
was eluted in 750 mL of QIAzol and processed for RNA isolation and
miRNA detection (see above). Exosomes and cells were lysed with
RIPA buffer (Santa Cruz Biotechnology) with an added protease in-
hibitor cocktail. Samples were centrifuged at 14,000  g for 15 min
at 4C, and the supernatant fractions were used for western blot.
Western blot was performed as previously described.46 The following
antibodies were used: Alix (Millipore, ABC40; 1:1,000; Merk Milli-
pore), Flotillin-1 (BD, 610820, 1:1,000), EPCAM (Cell Signaling
Technology, 2626; 1:1,000), CD63 (Abcam, ab59479; 1:1,000),
AGO2 (Abcam, ab57113; 1:1,000), DICER (Abcam, ab14601,
1:500), b-Actin (Sigma, A5441; 1:50,000), ECL Mouse IgG (GE
Healthcare, NA931; 1:2,000), and ECL Rabbit IgG (GE Healthcare,
NA934; 1:2,000).
Statistical Analysis
Comparisons between two different conditions were assessed using
the two-tailed Student’s t test. If the normality test failed, the
Mann-Whitney test was performed. Experiments with three or
more experimental groups were compared using one-way ANOVA
with either a post hoc Dunnett’s or Tukey’s multi-comparison test,
as appropriate. Toe survival was tested using log rank analysis. The
data are expressed as mean ± SEM. p values less than 0.05 were
considered to indicate statistical signiﬁcance (*p < 0.05, **p < 0.01,
***p % 0.001). Analyses were performed using Prism software
version 6 (Graph Pad).
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